Analysts/Institutional Investor Meet/Con. Call Updates

BDL/PKL/SEC/2026-27 10th September, 2026 The National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai – 400051 NSE SYMBOL:-BETA Subject: Intimation under Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding Analyst / Institutional Investor Meeting Respected Sir/Ma’am, Pursuant to Regulation 30 read with Schedule III (Part A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the management of the Company will be participating at the following event: Sr. Mode Date & Day Particulars Type of Meeting No. of Meeting September 17, 2026 Valorem Advisors a) (Thursday) at 4.00 Virtual Group Meet – Valorem CXO pm IST Meet We request you to kindly take the above information on your record. Thanking You Your’s faithfully For Beta Drugs Ltd. Rajni Brar Company Secretary Thursday, 17th September 2026 at 04:00 pm IST From the IR House that has brought you some of the most innovative and largest investor relation events, Valorem Advisors invites you to the virtual event: Valorem CXO Meet. The Valorem CXO Meet will host Directors/CXO’s from corporates over a virtual platform in a well-organized and structured manner, where management will discuss the company’s growth journey and provide insights into the industry, operations, performance, vision, strategy, and also address various questions from the investor community. Beta Drugs Ltd. 04:00 pm IST Click on logo for the investor kit link Mr. Rahul Batra Chairman & Managing Director ABOUT Beta Drugs Ltd. (BETA) is a specialty pharmaceutical company established in 2005, focused on oncology and expanding its presence across high-growth specialty therapies, including IVF and dermatology. The company has built a diversified business platform in specialty pharmaceuticals comprising branded formulations, contract manufacturing, APIs and exports, supported by its strong oncology franchise and growing presence across domestic and international markets. The company offers a comprehensive oncology portfolio with 180+ oncology-focused SKUs spanning chemotherapy, targeted and hormonal therapies across multiple dosage forms. Its products reach 85%+ of corporate and government hospitals in India, supported by focused R&D capabilities in innovative products and Novel Drug Delivery Systems (NDDS). The company operates 3 WHO-GMP certified manufacturing facilities, with one additionally accredited by ANVISA, INVIMA and COFEPRIS. It has a presence across 46+ countries, supported by 280+ dossier registrations and ~300 filed for registrations in multiple geographies, while its API business provides backward integration, with 65%+ of APIs used for in-house formulations. The company diversified through foray into the IVF products business with Nivian Lifesciences. Under its Vision 2030, the company aims to build an innovation-led specialty pharmaceutical platform, with a focus on expanding its branded portfolio, strengthening exports, enhancing manufacturing efficiency and pursuing strategic inorganic opportunities. The company has delivered a 5-year revenue CAGR of 27% and EBITDA CAGR of 25%, while maintaining healthy profitability, and is targeting a ~25% revenue CAGR through FY30, supported by its robust growth plans. Agenda: Rules: • Management Journey • Pre-registration required to get zoom • Industry Overview meeting invite • Business and Operational • All participants video and audio will be in Overview switched off mode Register Here • Financial Highlights • Participants can pre-request their questions Register Here • Future Growth Strategy in registration form or ask during the • Q&A meeting in zoom chat